Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 plus Rituximab in relapsed or refractory CLL
CTR20150541Phase 2Terminated
- Sponsor
- Ascentage Pharma
- Start
- May 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of r-(-)-gossypol acetic acid in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Ascentage Pharma. Started May 2017; status: terminated.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20150541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150541.